- Home
- MFA vs COLL Comparison
MFA vs COLL Comparison
Compare MFA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- COLL
- Stock Information
- Founded
- MFA 1997
- COLL 2002
- Country
- MFA United States
- COLL United States
- Employees
- MFA N/A
- COLL N/A
- Industry
- MFA Real Estate Investment Trusts
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- COLL Health Care
- Exchange
- MFA Nasdaq
- COLL Nasdaq
- Market Cap
- MFA 980.3M
- COLL 958.8M
- IPO Year
- MFA N/A
- COLL 2015
- Fundamental
- Price
- MFA $9.36
- COLL $32.52
- Analyst Decision
- MFA Buy
- COLL Strong Buy
- Analyst Count
- MFA 8
- COLL 4
- Target Price
- MFA $11.86
- COLL $43.75
- AVG Volume (30 Days)
- MFA 1.5M
- COLL 310.3K
- Earning Date
- MFA 08-06-2025
- COLL 08-07-2025
- Dividend Yield
- MFA 15.19%
- COLL N/A
- EPS Growth
- MFA N/A
- COLL N/A
- EPS
- MFA 0.99
- COLL 1.25
- Revenue
- MFA $292,245,000.00
- COLL $664,283,000.00
- Revenue This Year
- MFA N/A
- COLL $20.23
- Revenue Next Year
- MFA $14.73
- COLL $3.82
- P/E Ratio
- MFA $9.45
- COLL $25.92
- Revenue Growth
- MFA 52.95
- COLL 17.17
- 52 Week Low
- MFA $7.85
- COLL $23.23
- 52 Week High
- MFA $13.45
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- MFA 42.80
- COLL 69.85
- Support Level
- MFA $9.51
- COLL $30.60
- Resistance Level
- MFA $9.73
- COLL $33.22
- Average True Range (ATR)
- MFA 0.19
- COLL 0.85
- MACD
- MFA -0.02
- COLL 0.27
- Stochastic Oscillator
- MFA 17.27
- COLL 82.32
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.